Fulcrum Therapeutics (FULC) EBITDA (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of EBITDA data on file, last reported at -$22.2 million in Q1 2026.

• On a quarterly basis, EBITDA fell 8.74% year-over-year to -$22.2 million in Q1 2026; TTM through Mar 2026 was -$86.6 million, a 594.3% decrease from a year earlier, with the FY2025 full-year figure at -$84.8 million, down 287.13% from the prior year.
• EBITDA for Q1 2026 stood at -$22.2 million, up from -$22.7 million in the prior quarter.
• Over the last five years, EBITDA for FULC reached as high as $52.5 million in Q2 2024 and fell as low as -$34.2 million in Q2 2022.
• Historically, EBITDA has averaged -$20.7 million across 5 years, with a median of -$25.1 million in 2024.
• Across the five-year window, EBITDA surged 292.33% in 2024 and sank 137.75% in 2025, its largest moves.
• Year by year, EBITDA stood at -$28.0 million in 2022, then declined by 0.07% to -$28.0 million in 2023, then soared by 30.59% to -$19.4 million in 2024, then slipped by 16.8% to -$22.7 million in 2025, then climbed by 2.23% to -$22.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$22.2 million in Q1 2026, -$22.7 million in Q4 2025, and -$21.9 million in Q3 2025.